Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

Part of paid clinical trials in Austin, Texas.

Sponsor
AstraZeneca
Study ID
NCT01068756
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 45 Years
Healthy Volunteers
Accepted

Interventions

  • Dapagliflozin — DRUG
    Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days
  • Rifampin — DRUG
    Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days

Study Details

The purpose of the study is to assess the effects of rifampin on the pharmacokinetics of dapagliflozin

Key Dates

Start date
Mar 31, 2010
Status verified
Oct 2016
Primary completion
Apr 30, 2010
Completion
Apr 30, 2010

Study Design

Enrollment
14 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP

Arms

  • Other: Dapagliflozin/Rifampin

Primary Outcome Measure

AUC (area under the concentration-time curve) Single dose pharmacokinetic parameter will be derived from plasma concentration versus time data [ Time Frame: Days 1 to 3 and Days 9 to 11 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Ppd DevelopmentAustinTexas78744-

Find similar trials in Austin, TX

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Ppd Development· Austin, TX

Related Studies